share_log

JP Morgan Maintains Neutral on Global Blood Therapeutics, Lowers Price Target to $36

Benzinga Real-time News ·  Jun 28, 2022 10:08

JP Morgan analyst Tessa Romero maintains Global Blood Therapeutics (NASDAQ:GBT) with a Neutral and lowers the price target from $39 to $36.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment